Iatrogenic endometriosis harbors somatic cancer-driver mutations
Observational
OA: bronze
CC0
⤵ 72 in-corpus citations
AI-generated summary
This study found that approximately one-quarter of iatrogenic endometriosis cases harbor somatic cancer-driver mutations, commonly affecting MAPK/RAS or PI3K-Akt-mTor signaling pathways.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
STUDY QUESTION: Does incisional endometriosis (IE) harbor somatic cancer-driver mutations?
SUMMARY ANSWER: We found that approximately one-quarter of IE cases harbor somatic-cancer mutations, which commonly affect components of the MAPK/RAS or PI3K-Akt-mTor signaling pathways.
WHAT IS KNOWN ALREADY: Despite the classification of endometriosis as a benign gynecological disease, it shares key features with cancers such as resistance to apoptosis and stimulation of angiogenesis and is well-established as the precursor of clear cell and endometrioid ovarian carcinomas. Our group has recently shown that deep infiltrating endometriosis (DE), a form of endometriosis that rarely undergoes malignant transformation, harbors recurrent somatic mutations.
STUDY DESIGN, SIZE, DURATION: In a retrospective study comparing iatrogenically induced and endogenously occurring forms of endometriosis unlikely to progress to cancer, we examined endometriosis specimens from 40 women with IE and 36 women with DE. Specimens were collected between 2004 and 2017 from five hospital sites in either Canada, Germany or the Netherlands. IE and DE cohorts were age-matched and all women presented with histologically typical endometriosis without known history of malignancy.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Archival tissue specimens containing endometriotic lesions were macrodissected and/or laser-capture microdissected to enrich endometriotic stroma and epithelium and a hypersensitive cancer hotspot sequencing panel was used to assess for presence of somatic mutations. Mutations were subsequently validated using droplet digital PCR. PTEN and ARID1A immunohistochemistry (IHC) were performed as surrogates for somatic events resulting in functional loss of respective proteins.
MAIN RESULTS AND THE ROLE OF CHANCE: Overall, we detected somatic cancer-driver events in 11 of 40 (27.5%) IE cases and 13 of 36 (36.1%) DE cases, including hotspot mutations in KRAS, ERBB2, PIK3CA and CTNNB1. Heterogeneous PTEN loss occurred at similar rates in IE and DE (7/40 vs 5/36, respectively), whereas ARID1A loss only occurred in a single case of DE. While rates of detectable somatic cancer-driver events between IE and DE are not statistically significant (P > 0.05), KRAS activating mutations were more prevalent in DE.
LIMITATIONS, REASONS FOR CAUTION: Detection of somatic cancer-driver events were limited to hotspots analyzed in our panel-based sequencing assay and loss of protein expression by IHC from archival tissue. Whole genome or exome sequencing, or epigenetic analysis may uncover additional somatic alterations. Moreover, because of the descriptive nature of this study, the functional roles of identified mutations within the context of endometriosis remain unclear and causality cannot be established.
WIDER IMPLICATIONS OF THE FINDINGS: The alterations we report may be important in driving the growth and survival of endometriosis in ectopic regions of the body. Given the frequency of mutation in surgically displaced endometrium (IE), examination of similar somatic events in eutopic endometrium, as well as clinically annotated cases of other forms of endometriosis, in particular endometriomas that are most commonly linked to malignancy, is warranted.
STUDY FUNDING/COMPETING INTEREST(S): This study was funded by a Canadian Cancer Society Impact Grant [701603, PI Huntsman], Canadian Institutes of Health Research Transitional Open Operating Grant [MOP-142273, PI Yong], the Canadian Institutes of Health Research Foundation Grant [FDN-154290, PI Huntsman], the Canadian Institutes of Health Research Project Grant [PJT-156084, PIs Yong and Anglesio], and the Janet D. Cottrelle Foundation through the BC Cancer Foundation [PI Huntsman]. D.G. Huntsman is a co-founder and shareholder of Contextual Genomics Inc., a for profit company that provides clinical reporting to assist in cancer patient treatment. R. Aguirre-Hernandez, J. Khattra and L.M. Prentice have a patent MOLECULAR QUALITY ASSURANCE METHODS FOR USE IN SEQUENCING pending and are current (or former) employees of Contextual Genomics Inc. The remaining authors have no competing interests to declare.
TRIAL REGISTRATION NUMBER: Not applicable.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (54)
- Activation of mutated K-ras in donor endometrial epithelium and stroma promotes lesion growth in an intact immunocompetent murine model of endometriosis via openalex
- Angiogenic factors in endometriosis via openalex
- ARID1A mutations in endometriosis-associated ovarian carcinomas via openalex
- Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients via openalex
- Caesarean section greatly increases risk of scar endometriosis via openalex
- Caesarean section scar endometriosis: two cases of recurrent disease and a literature review via openalex
- Cancer-Associated Mutations in Endometriosis without Cancer via openalex
- Carcinosarcoma arising from atypical endometriosis in a cesarean section scar via openalex
- Clinical practice. Endometriosis via openalex
- Creating Solutions in Endometriosis: Global Collaboration through the World Endometriosis Research Foundation via openalex
- Creating Solutions in Endometriosis: Global Collaboration through the World Endometriosis Research Foundation: via openalex
- Endometriosis via openalex
- Endometriosis-associated Ovarian Cancers via openalex
- Endometriosis: pathogenesis and treatment via openalex
- Histopathological extent of rectal invasion by rectovaginal endometriosis via openalex
- Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries via openalex
- KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance via openalex
- Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial via openalex
- Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden via openalex
- Pericardial, pleural, and diaphragmatic endometriosis via openalex
- Quantitative expression of apoptosis-regulating genes in endometrium from women with and without endometriosis via openalex
- Reduction of apoptosis and proliferation in endometriosis via openalex
- Risk of Gynecologic Cancer According to the Type of Endometriosis via openalex
- Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer via openalex
- The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres via openalex
- World Endometriosis Society consensus on the classification of endometriosis via openalex
- W2071700883 via openalex
- W2068085420 via openalex
- W2156531035 via openalex
- W2065667074 via openalex
- W2346990949 via openalex
- W2410446908 via openalex
- W2416726113 via openalex
- W2558715006 via openalex
- W2580698996 via openalex
- W2608835133 via openalex
- W2050573392 via openalex
- W2634279167 via openalex
- W2027044610 via openalex
- W2748794530 via openalex
- W2761263615 via openalex
- W2001353514 via openalex
- W2782426754 via openalex
- W2800832479 via openalex
- W1978088642 via openalex
- W2891190591 via openalex
- W2904140705 via openalex
- W1977267072 via openalex
- W1970527559 via openalex
- W6714562450 via openalex
- W2125681453 via openalex
- W6716335006 via openalex
- W2133410449 via openalex
- W2138336325 via openalex
Cited by (50)
- Endometriosis lesions are oligoclonal structures derived from the normal endometrium 2026
- Somatic Cancer Driver Mutation Analysis in Endometriosis with Tumor-like Presentations: A Case Series Study 2026
- Genetic architecture of endometriosis: risk factors, comorbidities and clinical implications 2026
- Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making 2026
- Cancer-associated mutations in endometriosis reframe a benign disease through molecular oncology 2026
- Variation in endometriosis aetiology, potential impact on lesion heterogeneity and the consequences for research and treatment 2026
- M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy With Comorbid Traits 2025
- The role of somatic mutations in endometriosis: pathogenesis, progression, and fibrogenesis (narrative review) 2025
- Pathophysiology of Endometriosis: Insights from Immunohistochemical Analysis of Ectopic and Eutopic Tissues 2025
- Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma 2024
- Somatic PTEN and ARID1A loss and endometriosis disease burden: a longitudinal study 2024
- Genetically identification of endometriosis and cancers risk in women through a two-sample Mendelian randomization study 2024
- The long road of drug development for endometriosis - Pains, gains, and hopes 2024
- Oncological aspects of ovarian endometriosis 2024
- The Different Gene Expression Profile in the Eutopic and Ectopic Endometrium Sheds New Light on the Endometrial Seed in Endometriosis 2024
- Mechanism of quercetin in the treatment of endometriosis based on network pharmacology and transcriptome sequencing 2024
- The role of regulatory T-cells in the development of endometriosis 2024
- Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis 2023
- KRAS mutations and endometriosis burden of disease 2023
- Cell State of Origin Impacts Development of Distinct Endometriosis-Related Ovarian Carcinoma Histotypes 2023
- Iatrogenic Endometriosis of the Breast Mimicking Fat Necrosis: A Case Report 2023
- Endometriosis with colonic mucosal colonisation: a diagnostic confounder 2023
- Aberrant expression of histone deacetylase 8 in endometriosis and its potential as a therapeutic target 2023
- Genetics and genomics of endometriosis☆ 2023
- Digestive system deep infiltrating endometriosis: What do we know 2023
- Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics 2023
- New concepts on the etiology of endometriosis 2023
- Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis 2023
- Genomic Insults and their Redressal in the Eutopic Endometrium of Women with Endometriosis 2023
- Immune micro-environment and drug analysis of peritoneal endometriosis based on epithelial-mesenchymal transition classification 2022
- Malignancy Risks Associated with Endometriosis: Epidemiology 2022
- AP-1 Subunit JUNB Promotes Invasive Phenotypes in Endometriosis 2022
- Integrated bioinformatic analysis of dysregulated microRNA-mRNA co-expression network in ovarian endometriosis 2022
- Differential Expression of Long Non-coding Ribonucleic Acid (RNA) Genes in Endometriosis-associated Ovarian Cancer (EAOC): A Pilot Meta-analysis for Pathological Insights and Potential Diagnostic Biomarker Identification 2022
- Endometriosis Research: From Bench to Bedside 2022
- APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis 2022
- Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes 2022
- Challenges in Diagnosis and Prevention of Iatrogenic Endometriosis as a Long-Term Surgical Complication after C-Section 2022
- Endometriosis, the Silent Disease: Molecular Targets, Active Principles, and Drug Delivery Systems 2022
- A cellular and molecular portrait of endometriosis subtypes 2021
- The role of mutations in the PI3K/AKT/mTOR signal pathway in decreasing ovarian reserve in reproductive patients with deep infiltrative endometriosis 2021
- Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study 2021
- The role of mutations in the PI3K/AKT/mTOR- signal pathway in decreasing ovarian reserve in reproductive patients with deep infiltrative endometriosis 2021
- How Does Endometriosis Lead to Ovarian Cancer? The Molecular Mechanism of Endometriosis-Associated Ovarian Cancer Development 2021
- Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes 2021
- Biological significance of KRAS mutant allele expression in ovarian endometriosis 2021
- Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic KRAS and PIK3CA Mutations for Understanding the Underlying Biology and Molecular Pathogenesis 2021
- Target identification and drug discovery by data-driven hypothesis and experimental validation in ovarian endometriosis 2021
- Whole-Exome Sequencing of Rare Site Endometriosis-Associated Cancer 2021
- The Basic Science of Endometriosis 2020
Source provenance
- europepmc
- last seen: 2026-10-13T06:10:10.580696+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:23:25.915063+00:00
License: CC0
· commercial use OK